274 related articles for article (PubMed ID: 31611405)
1. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice.
Yang S; Siepka SM; Cox KH; Kumar V; de Groot M; Chelliah Y; Chen J; Tu B; Takahashi JS
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22229-22236. PubMed ID: 31611405
[TBL] [Abstract][Full Text] [Related]
2. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
3. Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.
Aponte JL; Sega GA; Hauser LJ; Dhar MS; Withrow CM; Carpenter DA; Rinchik EM; Culiat CT; Johnson DK
Proc Natl Acad Sci U S A; 2001 Jan; 98(2):641-5. PubMed ID: 11209059
[TBL] [Abstract][Full Text] [Related]
4. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Luijerink MC; Jacobs SM; van Beurden EA; Koornneef LP; Klomp LW; Berger R; van den Berg IE
J Hepatol; 2003 Dec; 39(6):901-9. PubMed ID: 14642604
[TBL] [Abstract][Full Text] [Related]
5. Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1.
Luijerink MC; van Beurden EA; Malingré HE; Jacobs SM; Grompe M; Klomp LW; Berger R; van den Berg IE
Kidney Int; 2004 Sep; 66(3):990-1000. PubMed ID: 15327392
[TBL] [Abstract][Full Text] [Related]
6. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1.
Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM
Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G; Tanguay RM
Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
[TBL] [Abstract][Full Text] [Related]
9. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
10. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
[TBL] [Abstract][Full Text] [Related]
11. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress.
Dieter MZ; Freshwater SL; Miller ML; Shertzer HG; Dalton TP; Nebert DW
Free Radic Biol Med; 2003 Aug; 35(4):351-67. PubMed ID: 12899938
[TBL] [Abstract][Full Text] [Related]
13. Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.
van Ginkel WG; van Vliet D; van der Goot E; Faassen MHJR; Vogel A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31623189
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
Grompe M; Overturf K; al-Dhalimy M; Finegold M
J Inherit Metab Dis; 1998 Aug; 21(5):518-31. PubMed ID: 9728332
[TBL] [Abstract][Full Text] [Related]
15. Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy.
Mohamed S; Kambal MA; Al Jurayyan NA; Al-Nemri A; Babiker A; Hasanato R; Al-Jarallah AS
BMC Res Notes; 2013 Sep; 6():362. PubMed ID: 24016420
[TBL] [Abstract][Full Text] [Related]
16. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
17. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
18. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.
Sun MS; Hattori S; Kubo S; Awata H; Matsuda I; Endo F
J Am Soc Nephrol; 2000 Feb; 11(2):291-300. PubMed ID: 10665936
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
20. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
